The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab

Cytotherapy

Volumn 8, Issue 1, 2006, Pages 13-23

  Kornacker, Martin ^a   Verneris, M R ^b   Kornacker, B ^a   Ganten, T M ^a   Scheffold, C ^b   Negrin, R S ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adoptive immunotherapy; Bispecific Ab; Cancer; Her2 neu; Killer cell expansion

Indexed keywords

B7 ANTIGEN; BENZYLOXYCARBONYLLEUCYLGLUTAMYLHISTIDYLASPARTYL FLUOROMETHYL KETONE; BISPECIFIC ANTIBODY; CASPASE INHIBITOR; CD3 ANTIBODY; CD86 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN F(AB')2 FRAGMENT; MONOCLONAL ANTIBODY CD28;

ADOPTIVE IMMUNOTHERAPY; ADULT; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; KILLER CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; OVARY CANCER; TARGET CELL;

ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; APOPTOSIS; BINDING SITES, ANTIBODY; CELL PROLIFERATION; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HUMANS; KILLER CELLS; MIDDLE AGED; NEOPLASMS; RECEPTOR, ERBB-2; RECEPTORS, CELL SURFACE; TUMOR CELLS, CULTURED;

EID: 33344469743     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240500518264     Document Type: Article

References (49)

1. Schmidt-Wolf, IG and Negrin, RS and Kiem, HP and (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity J Exp Med, 174, pp. 139 - 149.
2. Schmidt-Wolf, IG and Lefterova, P and Mehta, BA and (1993) Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells Exp Hematol, 21, pp. 1673 - 1679.
3. Schmidt-Wolf, IG and Lefterova, P and Johnston, V and (1994) Propagation of large numbers of T cells with natural killer cell markers Br J Haematol, 87, pp. 453 - 458.
4. Schmidt-Wolf, IG and Lefterova, P and Johnston, V and (1996) Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells Cell Immunol, 169, pp. 85 - 90.
5. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency J Immunol, 153, pp. 1687 - 1696.
6. + killer cells Blood, 86, pp. 3493 - 3499.
7. + T cells Blood, 103, pp. 3065 - 3072.
8. Hoyle, C and Bangs, CD and Chang, P and (1998) Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: In vitro and in vivo efficacy in severe combined immunodeficiency disease mice Blood, 92, pp. 3318 - 3327.
9. Leemhuis, T and Wells, S and Scheffold, C and (2005) A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma Biol Blood Marrow Transplant, 11, pp. 181 - 187.
10. Shalaby, MR and Carter, P and Maneval, D and (1995) Bispecific HER2xCD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice Clin Immunol Immunopathol, 74, pp. 185 - 192.
11. + natural killer T cells redirected with bispecific antibody F(ab'(2)HER2xCD3 Cancer Res, 62, pp. 5785 - 5791.
12. Bruenke, J and Barbin, K and Kunert, S and (2005) Effective lysis of lymphoma cells with a stabilized bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16) Br J Hematol, 130, pp. 218 - 228.
13. Schlereht, B and Fichtner, I and Lorenczewski, G and (2005) Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/ CD3-bispecific antibody construct Cancer Res, 65, pp. 2882 - 2889.
14. Verneris, MR and Arshi, A and Edinger, M and (2005) Low levels of Her2/ neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells Clin Cancer Res, 11, pp. 4561 - 4570.
15. Shalaby, MR and Shepard, HM and Presta, L and (1992) Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene J Exp Med, 175, pp. 217 - 225.
16. Koelemij, R and Kuppen, PJ and van de Velde, CJ and (1999) Bispecific antibodies in cancer therapy, from the laboratory to the clinic J Immunother, 22, pp. 514 - 524.
17. Manzke, O and Tesch, H and Lorenzen, J and (2001) Locoregional treatment of low-grade-B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses Int J Cancer, 9, pp. 516 - 522.
18. Stemmler, HJ and Salat, C and Lindhofer, H and (2005) Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: A pilot study Anticancer Res, 25, pp. 30478 - 30554.
19. Lasfargues, EY and Coutinho, WG and Redfield, ES. (1978) Isolation of two human tumor epithelial cell lines from solid breast carcinomas J Natl Cancer Inst, 61, pp. 967 - 978.
20. FoghJ.Human Tumor Cells In Vitro. New York: Plenum Press, 1975.
21. 2 formation in Escherichia coli and for improved in vivo stability J Immunol, 151, pp. 6954 - 6961.
22. Carter, P and Kelley, RF and Rodrigues, ML and (1992) High level Escherichia coli expression and production of a bivalent humanized antibody fragment Biotechnol (NY), 10, pp. 163 - 167.
23. 2 fragment for improved binding to T cells Int J Cancer, 7 (Suppl), pp. 45 - 50.
24. Yokota, J and Yamamoto, T and Toyoshima, K and (1986) Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo Lancet, 1(8484), pp. 765 - 767.
25. Collette, Y and Benziane, A and Razanajaona, D and (1998) Distinct regulation of T-cell death by CD28 depending on both its aggregation and T-cell receptor triggering: A role for Fas-FasL Blood, 92, pp. 1350 - 1356.
26. Daniel, PT and Kroidl, A and Cayeux, S and (1997) Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis J Immunol, 159, pp. 3808 - 3815.
27. Alderson, MR and Tough, TW and Davis-Smith, T and (1995) Fas ligand mediates activation-induced cell death in human T lymphocytes J Exp Med, 181, pp. 71 - 77.
28. Boise, L and Minn, A and Noel, P and (1995) CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL Immunity, 3, pp. 87 - 98.
29. Daniel, PT and Kroidl, A and Kopp, J and (1998) Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: Costimulation via CD28 prevents 'veto' apoptosis of antibody-targeted cytotoxic T cells Blood, 92, pp. 4750 - 4757.
30. Zhu, H and Fearnhead, HO and Cohen, GM. (1995) An ICE-like protease is a common mediator of apoptosis induced by diverse stimuli in human monocytic THP.1 cells FEBS Lett, 374, pp. 303 - 308.
31. + natural-killer-like T lymphocytes to EpCAM-expressing tumor cells Cancer Immunol Immunother., 49, pp. 441 - 448.
32. Lum, LG and Davol, PA. (2005) Retargeting T cells and immune effector cells with bispecific antibodies Cancer Chemother Biol Response Modif, 22, pp. 273 - 291.
33. Acuto, O and Michel, F. (2003) CD28-mediated co-stimulation: A quantitative support for TCR signalling Nat Rev Immunol, 3, pp. 939 - 951.
34. Green, DR and Scott, DW. (1994) Activation-induced apoptosis in lymphocytes Curr Opin Immunol, 6, pp. 476 - 487.
35. Brunner, T and Mogil, RJ and LaFace, D and (1995) Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas Nature, 373, pp. 441 - 444.
36. Dhein, J and Walczak, H and Baumler, C and (1995) Autocrine T-cell suicide mediated by APO-1/ Nature, 373, pp. 438 - 441.
37. Strasser, A. (1995) Apoptosis. Death of a T cell Nature, 373, pp. 385 - 386.
38. Ryan, AE and Shanahan, F and O'Connell, J and (2005) Addressing the 'Fas counterattack' controversy: Blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo Cancer Res, 65, pp. 9817 - 9823.
39. + T cells to Fas-mediated apoptosis Cancer Immunol Immunother, 49, pp. 335 - 345.
40. Martin, SJ and Reutelingsperger, CP and McGahon, AJ and (1995) Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl J Exp Med, 182, pp. 1545 - 1556.
41. Bacso, Z and Everson, RB and Eliason, JF. (2005) The DNA of annexin V-binding apoptotic cells is highly fragmented Cancer Res, 60, pp. 4623 - 4628.
42. Martinez-Lorenzo, MJ and Anel, A and Gamen, S and (1999) Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles J Immunol, 163, pp. 1274 - 1281.
43. Sansom, DM and Wilson, A and Boshell, M and (1993) B7/CD28 but not LFA-3/ CD2 interactions can provide 'third-party' co-stimulation for human T-cell activation Immunology, 80, pp. 242 - 247.
44. Nicholson, DW. (2000) From bench to clinic with apoptosis-based therapeutic agents Nature, 407, pp. 810 - 816.
45. Hotchkiss, RS and Chang, KC and Swanson, PE and (2000) Caspase inhibitors improve survival in sepsis: A critical role of the lymphocyte Nat Immunol, 1, pp. 496 - 501.
46. Spaner, D and Raju, K and Rabinovich, B and (1999) A role for perforin in activation-induced T cell death in vivo: Increased expansion of allogeneic perforin-deficient T cells in SCID mice J Immunol, 162, pp. 1192 - 1199.
47. Bidère, N and Senik, A. (2001) Caspase-independent apoptotic pathways in T lymphocytes: A minireview Apoptosis, 6, pp. 371 - 375.
48. DDavidson, WF and Haudenschild, C and Kwon, J and (2002) T cell receptor ligation triggers novel nonapoptotic cell death pathways that are Fas-independent or Fas-dependent J Immunol, 169, pp. 6218 - 6230.
49. Methot, N and Huang, J and Coulombe, N and (2004) Differential efficacy of caspase inhibitors on apoptosis markers during sepsis in rats and implication for fractional inhibition requirements for therapeutics J Exp Med, 199, pp. 199 - 207.